Back to Search
Start Over
Bioenergetic differences selectively sensitize tumorigenic liver progenitor cells to a new gold(I) compound.
- Source :
-
Carcinogenesis [Carcinogenesis] 2008 Jun; Vol. 29 (6), pp. 1124-33. Date of Electronic Publication: 2008 Apr 15. - Publication Year :
- 2008
-
Abstract
- A hallmark of cancer cells is their ability to evade apoptosis and mitochondria play a critical role in this process. Delineating mitochondrial differences between normal and cancer cells has proven challenging due to the lack of matched cell lines. Here, we compare two matched liver progenitor cell (LPC) lines, one non-tumorigenic [p53-immortalized liver (PIL) 4] and the other tumorigenic (PIL2). Analysis of these cell lines and a p53 wild-type non-tumorigenic cell line [bipotential murine oval liver (BMOL)] revealed an increase in expression of genes encoding the antiapoptotic proteins cellular inhibitor of apoptosis protein (cIAP) 1 and yes associate protein in the PIL2 cells, which resulted in an increase in the protein encoded by these genes. PIL2 cells have higher mitochondrial membrane potential (Deltapsi(m)) compared with PIL4 and BMOL and had greater levels of reactive oxygen species, despite the fact that the mitochondrial antioxidant enzyme, manganese superoxide disumutase, was elevated at transcript and protein levels. Taken together, these results may account for the observed resistance of PIL2 cells to apoptotic stimuli compared with PIL4. We tested a new gold compound to show that hyperpolarized Deltapsi(m) led to its increased accumulation in mitochondria of PIL2 cells. This compound selectively induces apoptosis in PIL2 cells but not in PIL4 or BMOL. The gold compound depolarized the Deltapsi(m), depleted the adenosine triphosphate pool and activated caspase-3 and caspase-9, suggesting that apoptosis was mediated via mitochondria. This investigation shows that the non-tumorigenic and tumorigenic LPCs are useful models to delineate the role of mitochondrial dysfunction in tumorigenesis and for the future development of mitochondria-targeted chemotherapeutics that selectively target tumor cells.
- Subjects :
- Adaptor Proteins, Signal Transducing metabolism
Animals
Apoptosis drug effects
Apoptosis physiology
Cell Cycle Proteins
Cell Line, Tumor
Drug Resistance, Neoplasm physiology
Gene Expression
Gene Expression Regulation, Neoplastic
Hepatocytes cytology
Immunoblotting
Inhibitor of Apoptosis Proteins metabolism
Membrane Potential, Mitochondrial drug effects
Membrane Potential, Mitochondrial physiology
Mice
Microarray Analysis
Mitochondria metabolism
Phosphoproteins metabolism
Reactive Oxygen Species metabolism
Reverse Transcriptase Polymerase Chain Reaction
Stem Cells drug effects
YAP-Signaling Proteins
Antineoplastic Agents pharmacology
Energy Metabolism
Gold Compounds pharmacology
Hepatocytes metabolism
Mitochondria drug effects
Stem Cells metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1460-2180
- Volume :
- 29
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Carcinogenesis
- Publication Type :
- Academic Journal
- Accession number :
- 18413365
- Full Text :
- https://doi.org/10.1093/carcin/bgn093